AOBiome trial to test live bacteria for acne treatment

AOBiome announced the launch recently of a phase 2b trial for its live topical bacterial therapy to treat acne in adults.

Results from the company’s phase 1b/2a dose-ranging safety study showed no serious adverse events and no difference in adverse events between treatment and vehicle groups, according to a company press release.

The phase 2b trial will be jointly conducted with Science 37, a clinical research organization, to utilize telemedicine-based approaches for data retrieval.

Approximately 372 adult patients have been enrolled for the treatment of mild-to-moderate acne vulgaris. The patients will use smartphones to collect real-time information and visual data as well as track progress while using the company’s ammonia-oxidizing bacteria.

“With the remarkable outcome of the phase 1b/2a study, we are excited to see the results of this upcoming phase 2b trial with Science 37, which will feature one-to-one randomized, double blind and placebo-controlled doses, over the course of 12 weeks,” Larry Weiss, MD, chief medical officer of AOBiome, said in the release. “AOB’s unique safety profile allows us to reach more patients and to rapidly test for clinical efficacy across multiple diseases states, with acne being the first.”

The skin microbiome company expects to complete the study by the third quarter of 2017.

Reference: www.aobiome.com